Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 14/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041608 | 0.94 | CAMK2D (0.40) | CAMK2DJAK3FGFR1PTK2JAK1 | |
| SCHEMBL15034946 | 0.84 | CAMK2D (0.38) | CAMK2DJAK3FGFR1TNK2SRC | |
| SCHEMBL15034798 | 0.82 | TNK2 (0.36) | CAMK2DJAK3FGFR1TNK2SRC | |
| SCHEMBL15035884 | 0.81 | CAMK2D (0.37) | CAMK2DJAK3PTK2TNK2SRC | |
| SCHEMBL15035708 | 0.80 | CAMK2D (0.36) | CAMK2DJAK3FGFR1TNK2SRC | |
| SCHEMBL15035914 | 0.80 | CAMK2D (0.38) | CAMK2DJAK3TNK2SRCEGFR | |
| SCHEMBL15237016 | 0.79 | TNK2 (0.38) | CAMK2DJAK3FGFR1TNK2SRC | |
| SCHEMBL15035056 | 0.78 | CAMK2D (0.37) | CAMK2DJAK3FGFR1TNK2SRC | |
| SCHEMBL15041189 | 0.78 | CAMK2D (0.39) | CAMK2DJAK3FGFR1TNK2SRC | |
| SCHEMBL15237025 | 0.78 | TNK2 (0.40) | CAMK2DJAK3TNK2SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | CAMK2D 146/4885JAK3 525/4885FGFR1 2209/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CAMK2D 469/4885JAK3 1901/4885FGFR1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.